Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
28.76
-0.21 (-0.72%)
Aug 14, 2025, 11:37 AM - Market open
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
According to 14 professional analysts, the 12-month price target for Ultragenyx Pharmaceutical stock ranges from a low of $34 to a high of $140. The average analyst price target of $86.64 forecasts a 201.25% increase in the stock price over the next year.
Price Target: $86.64 (+201.25%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 6 | 5 |
| Buy | 8 | 8 | 10 | 9 | 9 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 17 | 15 | 16 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $136 → $128 | Strong Buy | Maintains | $136 → $128 | +345.06% | Aug 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $112 → $105 | Buy | Maintains | $112 → $105 | +265.09% | Aug 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +178.16% | Jul 28, 2025 |
| Wedbush | Wedbush | Hold Maintains $35 → $34 | Hold | Maintains | $35 → $34 | +18.22% | Jul 14, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $65 → $55 | Buy | Maintains | $65 → $55 | +91.24% | Jul 14, 2025 |
Financial Forecast
Revenue This Year
665.02M
from 560.23M
Increased by 18.70%
Revenue Next Year
842.97M
from 665.02M
Increased by 26.76%
EPS This Year
-5.00
from -6.29
EPS Next Year
-3.48
from -5.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 701.8M | 1.1B | 1.9B | ||
| Avg | 665.0M | 843.0M | 1.2B | ||
| Low | 620.0M | 651.1M | 779.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.3% | 60.7% | 119.7% | ||
| Avg | 18.7% | 26.8% | 47.5% | ||
| Low | 10.7% | -2.1% | -7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.85 | -0.86 | 1.84 | ||
| Avg | -5.00 | -3.48 | -0.72 | ||
| Low | -6.89 | -5.27 | -3.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.